Yahoo Web Search

  • FirefoxTry Yahoo Search on Firefox »
    1. Sort by

    1. HACKENSACK, N.J. and PETACH TIKVAH, Israel, Sept. 2, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, ...

    2. BCLI: Phase 2 ALS Trial Fully Enrolled; Data in Mid-2016…

      Zacks Small Cap Research via Yahoo! FinanceAug 17 08:30 AM

      On August 10, 2015, BrainStorm announced the completion of enrollment of 48 patients in the company’s ongoing, randomized, double blind, placebo controlled Phase 2 clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS). BrainStorm is developing adult stem cells therapies for the treatment of a range of neurodegenerative diseases, including ALS, Autism, Multiple Sclerosis (MS), and ...

    3. HACKENSACK, N.J. and PETACH TIKVAH, Israel, Aug. 11, 2015 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has completed enrollment in its ongoing randomized, double-blind placebo-controlled phase 2 clinical trial of NurOwn® in amyotrophic lateral sclerosis (ALS).  The targeted ...

    4. HACKENSACK, N.J. and PETACH TIKVAH, Israel, Aug. 13, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, ...

    5. NEW YORK and PETACH TIKVAH, Israel, Aug. 6, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced ...

    6. BrainStorm Cell Therapeutics ( BCLI +7.6% ) Q2 results : Revenues: $0; R&D Expense: $1.4M (+55.6%); SG&A: $1M (+150.0%); Operating Loss: ($2.4M) (-84.6%); Net Loss: ($2.3M) (-15.0%); Loss Per Share: ($0.12) (+25.0%); Quick Assets: $1.3M (-69.8%); CF Ops: ($1.7M) (-70%).

    7. The Alliance for Regenerative Medicine , the international advocacy organization representing the interests of the advanced therapies and regenerative medicine community, today announced the initial slate ...

    8. INGN Lifts Outlook, BCLI Awaits DSMB Review, TRVN To Report Data Next Month

    9. Sizing Up the Retail Sector's Earnings Picture - Earnings Preview

    1. 1214 results